POZEN
Quick facts
Marketed products
- aspirin and [NSAID] · Pain management / Cardiovascular
This combination product pairs aspirin with an NSAID to provide anti-inflammatory and analgesic effects while potentially reducing gastrointestinal toxicity through a fixed-dose formulation. - celebrex · Immunology
- EC Aspirin 325 · Cardiovascular
EC Aspirin 325 is an enteric-coated formulation of aspirin that inhibits platelet cyclooxygenase to prevent blood clots and reduce inflammation. - Sumatriptan and Naproxen sodium · Neurology
Sumatriptan activates serotonin 5-HT1B/1D receptors to relieve migraine pain, while naproxen sodium inhibits cyclooxygenase enzymes to reduce inflammation and provide additional analgesic effect.
Phase 3 pipeline
- PA32540 · Pain Management
PA32540 is a fixed-dose combination of acetaminophen and a nonsteroidal anti-inflammatory drug (NSAID) designed to provide enhanced pain relief with potentially improved gastrointestinal safety. - PN 400 (VIMOVO) · Gastrointestinal
VIMOVO combines the NSAID ibuprofen with the proton pump inhibitor omeprazole to reduce gastrointestinal side effects associated with NSAID therapy. - Rescue Antacid · Gastroenterology
Rescue Antacid neutralizes stomach acid to provide rapid relief from heartburn and acid indigestion.
Phase 1 pipeline
- aspirin component of PA32540
- EC esomeprazole
- EC naproxen
- EC naproxen plus EC esomeprazole
- Ecotrin · Other
- PA32540 and celecoxib
- Plavix® and PA32540
- PN 200
- PN 400
- PN400
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: